Back to resultsA Study of Atezolizumab Compared With Gemcitabine Plus (+) Cisplatin or Carboplatin for PD-L1-Selected Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower111)
Primary Purpose
Non-Small Cell Lung Cancer
Status
Terminated
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Atezolizumab
Carboplatin
Cisplatin
Gemcitabine
Sponsored by
About this trial
This is an interventional treatment trial for Non-Small Cell Lung Cancer
Eligibility Criteria
Inclusion Criteria:
- Histologically or cytologically confirmed Stage IV squamous NSCLC
- Tumor programmed death-ligand 1 (PD-L1) expression, as determined by immunohistochemistry (IHC) assay of archival tumor tissue or tissue obtained at screening
- No prior treatment for Stage IV squamous NSCLC
- Measurable disease as defined by RECIST v1.1
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
- Adequate hematologic and end-organ function
Exclusion Criteria:
- Active or untreated central nervous system (CNS) metastases
- Untreated or inadequately treated spinal cord compression
- Leptomeningeal disease
- Uncontrolled pleural effusion, pericardial effusion, or ascites
- Uncontrolled tumor-related pain
- Uncontrolled hypercalcemia
- Any other malignancies within 5 years except those with negligible risk of metastasis or death
- Pregnant or lactating women
- Known hypersensitivity to any component of atezolizumab formulation or other study medication
- History of autoimmune disease except controlled, treated hypothyroidism or type I diabetes
- Prior allogeneic bone marrow or solid organ transplantation
- Positive human immunodeficiency virus (HIV) test
- Active hepatitis B or C
- Active tuberculosis
- Significant cardiovascular disease
- Severe infection or major surgery within 4 weeks prior to randomization
- Use of any approved anti-cancer therapy within 3 weeks prior to treatment
- Use of an investigational agent or participation in another clinical trial within 4 weeks prior to randomization
- Exposure to oral or IV antibiotics within 2 weeks or live attenuated vaccines within 4 weeks prior to randomization
- Prior treatment with cluster of differentiation (CD) 137 agonists or immune checkpoint blockade therapies, anti-programmed death-1 (anti-PD-1), and anti-PD-L1 therapeutic antibodies
- Treatment with immunostimulatory agents within 4 weeks or immunosuppressive agents within 2 weeks prior to randomization
Sites / Locations
- California Cancer Associates for Research & Excellence, Inc.
- Marin Cancer Care Inc
- University of California San Diego
- Chao Family Comprehensive Cancer Center; UC Irvine Medical Center
- Eastern Connecticut Hematology and Oncology Associates; (ECHO)
- Georgetown University Medical Center
- Mount Sinai Medical Center
- Florida Hospital
- Straub Clinic & Hospital; Oncology
- Ingalls Memorial Hospital
- Consultants in Blood Disorders & Cancer
- University of Maryland
- Bay Hematology Oncology
- Montana Cancer Specialists
- Atlantic Health Cancer Center
- Montefiore Medical Center
- Maimonides Medical Center
- Presbyterian Hospital
- Carolina Oncology Specialists, PA - Hickory
- First Health of the Carolinas
- Penn State Milton S. Hershey Medical Center
- Spartanburg Regional Medical Center
- Wellmont Cancer Institute
- University Oncology Associates
- Sarah Cannon Cancer Center
- Vanderbilt Medical Center
- MultiCare Regional Cancer Center - Auburn
- West Virginia University Hospital
- Multiscan s.r.o.
- Hôpital du Cluzeau
- Hopital Tenon; Oncologie Radiotherapie
- Centre Paul Strauss
- KRH Klinikum Siloah-Oststadt-Heidehaus
- Brüderkrankenhaus St. Josef Paderborn
- Sotiria Chest Hospital of Athens
- Attikon University General Hospital
- Bioclinic Thessaloniki
- Georgios Papanikolaou General Hosp. of Thessaloniki
- Semmelweis Egyetem
- Uzsoki Utcai Korhaz
- Matrai Gyogyintezet
- Szabolcs-Szatmar-Bereg Megyei; Korhazak es Egyetemi Oktatokorhaz
- University of Pecs, I st Dept of Internal Medicine
- Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz-Rend.Int.
- IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica
- Ospedale Infermi di Rimini
- Irccs Centro Di Riferimento Oncologico (CRO)
- Asst Papa Giovanni XXIII
- Azienda Ospedaliera Istituti Ospitalieri
- Ospedale San Raffaele S.r.l.
- Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 2
- Istituto Europeo Di Oncologia
- Asst Di Monza
- Istituto Clinico Humanitas
- Azienda Ospedaliera Città della Salute e della Scienza di Torino
- A.O.U.I. VERONA-OSPEDALE BORGO TRENTO; ONCOLODIA MEDICA-d.O.
- Seoul National University Bundang Hospital
- Chonnam National University Hwasun Hospital
- The Catholic University of Korea St. Vincent's Hospital
- Uniwersyteckie Centrum Kliniczne
- County Hospital Alba; Oncology
- Dr Constantin Opris Emergency County Hospital Baia Mare
- Teo Health SA - Saint Constantin Hospital
- Oncology Center Sf. Nectarie
- Institutul Regional de Oncologie Iasi; Clinica de Hematologie
- Sibiu Emergency Clinical County Hospital
- Oncomed SRL
- Arkhangelsk Regional Clinical Oncology Dispensary
- Kursk Regional Clinical Oncology Dispensary
- Filial #1 Regional Oncology Dispensary of Nizhniy Novgorod
- Mordovia State University
- Leningrad Regional Clinical Hospital
- Clinical Hospital Center Bezanijska kosa; Clinic for Oncology
- Clin Hospital Center - Kragujevac; Pulmonary Diseases
- Institute of Lung Diseases Vojvodina
- Hospital Universitari Germans Trias i Pujol; Servicio de Oncologia
- Fundacion Investigacion Hospital La Fe de Valencia
- Hosp Clinico Univ Lozano Blesa
- Birmingham Heartlands Hospital
- Diana Princess of Wales Hosp.
- Sarah Cannon Research Institute
- Christie Hospital NHS Trust
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Atezolizumab
Gemcitabine + Cisplatin/Carboplatin
Arm Description
Participants will receive intravenous (IV) infusion of atezolizumab once on Day 1 of each 21-day cycle until loss of clinical benefit.
Participants will receive IV infusion of gemcitabine + cisplatin or gemcitabine + carboplatin once on Day 1 of each 21-day cycle for four or six cycles as per local standard of care.
Outcomes
Primary Outcome Measures
Progression-Free Survival (PFS) as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02409355
Brief Title
A Study of Atezolizumab Compared With Gemcitabine Plus (+) Cisplatin or Carboplatin for PD-L1-Selected Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower111)
Official Title
A Phase III, Open-Label, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) Compared With Gemcitabine+Cisplatin or Carboplatin for PD-L1-Selected, Chemotherapy Naive Patients With Stage IV Squamous Non-Small Cell Lung Cancer
Study Type
Interventional
2. Study Status
Record Verification Date
February 2019
Overall Recruitment Status
Terminated
Why Stopped
The study was closed due to low patient enrollment and the Sponsor's decision to include patients with squamous NSCLC into the GO29431 study, NCT02409342.
Study Start Date
May 7, 2015 (Actual)
Primary Completion Date
December 7, 2017 (Actual)
Study Completion Date
December 7, 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hoffmann-La Roche
4. Oversight
5. Study Description
Brief Summary
This randomized, open-label study was designed to evaluate and compare the safety and efficacy of atezolizumab with gemcitabine + cisplatin or carboplatin in PD-L1 selected participants with chemotherapy-naive, Stage IV squamous NSCLC. The study was closed due to low patient enrollment and the Sponsor's decision to include patients with squamous NSCLC into the GO29431 study, NCT02409342. Therefore the planned objectives of this study are no longer applicable and formal analyses of efficacy or safety have not been performed.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Non-Small Cell Lung Cancer
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
8 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Atezolizumab
Arm Type
Experimental
Arm Description
Participants will receive intravenous (IV) infusion of atezolizumab once on Day 1 of each 21-day cycle until loss of clinical benefit.
Arm Title
Gemcitabine + Cisplatin/Carboplatin
Arm Type
Active Comparator
Arm Description
Participants will receive IV infusion of gemcitabine + cisplatin or gemcitabine + carboplatin once on Day 1 of each 21-day cycle for four or six cycles as per local standard of care.
Intervention Type
Drug
Intervention Name(s)
Atezolizumab
Other Intervention Name(s)
MPDL3280A; Tecentriq
Intervention Description
Atezolizumab will be administered at a dose of 1200 milligrams (mg) by IV infusion on Day 1 of each 21-day cycle until loss of clinical benefit.
Intervention Type
Drug
Intervention Name(s)
Carboplatin
Intervention Description
Carboplatin will be administered at area under the concentration-time curve (AUC) 5 IV infusion once on Day 1 of each 21-day cycle for 4 or 6 cycles.
Intervention Type
Drug
Intervention Name(s)
Cisplatin
Intervention Description
Cisplatin will be administered at 75 milligrams per square meter (mg/m^2) IV infusion once on Day 1 of each 21-day cycle for 4 or 6 cycles.
Intervention Type
Drug
Intervention Name(s)
Gemcitabine
Intervention Description
Gemcitabine will be administered at 1000 mg/m^2 (when coadministered with carboplatin) or 1250 mg/m^2 (when coadministered with cisplatin) IV infusion on Days 1 and 8 of each 21-day cycle for 4 or 6 cycles.
Primary Outcome Measure Information:
Title
Progression-Free Survival (PFS) as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)
Time Frame
Baseline up to death or disease progression, whichever occurs first (up to approximately 2.5 years)
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Histologically or cytologically confirmed Stage IV squamous NSCLC
Tumor programmed death-ligand 1 (PD-L1) expression, as determined by immunohistochemistry (IHC) assay of archival tumor tissue or tissue obtained at screening
No prior treatment for Stage IV squamous NSCLC
Measurable disease as defined by RECIST v1.1
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
Adequate hematologic and end-organ function
Exclusion Criteria:
Active or untreated central nervous system (CNS) metastases
Untreated or inadequately treated spinal cord compression
Leptomeningeal disease
Uncontrolled pleural effusion, pericardial effusion, or ascites
Uncontrolled tumor-related pain
Uncontrolled hypercalcemia
Any other malignancies within 5 years except those with negligible risk of metastasis or death
Pregnant or lactating women
Known hypersensitivity to any component of atezolizumab formulation or other study medication
History of autoimmune disease except controlled, treated hypothyroidism or type I diabetes
Prior allogeneic bone marrow or solid organ transplantation
Positive human immunodeficiency virus (HIV) test
Active hepatitis B or C
Active tuberculosis
Significant cardiovascular disease
Severe infection or major surgery within 4 weeks prior to randomization
Use of any approved anti-cancer therapy within 3 weeks prior to treatment
Use of an investigational agent or participation in another clinical trial within 4 weeks prior to randomization
Exposure to oral or IV antibiotics within 2 weeks or live attenuated vaccines within 4 weeks prior to randomization
Prior treatment with cluster of differentiation (CD) 137 agonists or immune checkpoint blockade therapies, anti-programmed death-1 (anti-PD-1), and anti-PD-L1 therapeutic antibodies
Treatment with immunostimulatory agents within 4 weeks or immunosuppressive agents within 2 weeks prior to randomization
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Clinical Trials
Organizational Affiliation
Hoffmann-La Roche
Official's Role
Study Director
Facility Information:
Facility Name
California Cancer Associates for Research & Excellence, Inc.
City
Encinitas
State/Province
California
ZIP/Postal Code
92008
Country
United States
Facility Name
Marin Cancer Care Inc
City
Greenbrae
State/Province
California
ZIP/Postal Code
94904
Country
United States
Facility Name
University of California San Diego
City
La Jolla
State/Province
California
ZIP/Postal Code
92093
Country
United States
Facility Name
Chao Family Comprehensive Cancer Center; UC Irvine Medical Center
City
Orange
State/Province
California
ZIP/Postal Code
92868
Country
United States
Facility Name
Eastern Connecticut Hematology and Oncology Associates; (ECHO)
City
Norwich
State/Province
Connecticut
ZIP/Postal Code
06360
Country
United States
Facility Name
Georgetown University Medical Center
City
Washington
State/Province
District of Columbia
ZIP/Postal Code
20007
Country
United States
Facility Name
Mount Sinai Medical Center
City
Miami Beach
State/Province
Florida
ZIP/Postal Code
33140
Country
United States
Facility Name
Florida Hospital
City
Orlando
State/Province
Florida
ZIP/Postal Code
32803
Country
United States
Facility Name
Straub Clinic & Hospital; Oncology
City
Honolulu
State/Province
Hawaii
ZIP/Postal Code
96813
Country
United States
Facility Name
Ingalls Memorial Hospital
City
Harvey
State/Province
Illinois
ZIP/Postal Code
60426
Country
United States
Facility Name
Consultants in Blood Disorders & Cancer
City
Louisville
State/Province
Kentucky
ZIP/Postal Code
40207
Country
United States
Facility Name
University of Maryland
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21201
Country
United States
Facility Name
Bay Hematology Oncology
City
Easton
State/Province
Maryland
ZIP/Postal Code
21601
Country
United States
Facility Name
Montana Cancer Specialists
City
Missoula
State/Province
Montana
ZIP/Postal Code
59802
Country
United States
Facility Name
Atlantic Health Cancer Center
City
Summit
State/Province
New Jersey
ZIP/Postal Code
07902
Country
United States
Facility Name
Montefiore Medical Center
City
Bronx
State/Province
New York
ZIP/Postal Code
10467
Country
United States
Facility Name
Maimonides Medical Center
City
Brooklyn
State/Province
New York
ZIP/Postal Code
11219
Country
United States
Facility Name
Presbyterian Hospital
City
Charlotte
State/Province
North Carolina
ZIP/Postal Code
28204
Country
United States
Facility Name
Carolina Oncology Specialists, PA - Hickory
City
Hickory
State/Province
North Carolina
ZIP/Postal Code
28602
Country
United States
Facility Name
First Health of the Carolinas
City
Pinehurst
State/Province
North Carolina
ZIP/Postal Code
28374
Country
United States
Facility Name
Penn State Milton S. Hershey Medical Center
City
Hershey
State/Province
Pennsylvania
ZIP/Postal Code
17033
Country
United States
Facility Name
Spartanburg Regional Medical Center
City
Spartanburg
State/Province
South Carolina
ZIP/Postal Code
29303
Country
United States
Facility Name
Wellmont Cancer Institute
City
Bristol
State/Province
Tennessee
ZIP/Postal Code
37620
Country
United States
Facility Name
University Oncology Associates
City
Chattanooga
State/Province
Tennessee
ZIP/Postal Code
37403
Country
United States
Facility Name
Sarah Cannon Cancer Center
City
Germantown
State/Province
Tennessee
ZIP/Postal Code
38138
Country
United States
Facility Name
Vanderbilt Medical Center
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37232-7610
Country
United States
Facility Name
MultiCare Regional Cancer Center - Auburn
City
Auburn
State/Province
Washington
ZIP/Postal Code
98002-4117
Country
United States
Facility Name
West Virginia University Hospital
City
Morgantown
State/Province
West Virginia
ZIP/Postal Code
26506
Country
United States
Facility Name
Multiscan s.r.o.
City
Pardubice
ZIP/Postal Code
532 03
Country
Czechia
Facility Name
Hôpital du Cluzeau
City
Limoges
ZIP/Postal Code
87042
Country
France
Facility Name
Hopital Tenon; Oncologie Radiotherapie
City
Paris
ZIP/Postal Code
75970
Country
France
Facility Name
Centre Paul Strauss
City
Strasbourg
ZIP/Postal Code
67085
Country
France
Facility Name
KRH Klinikum Siloah-Oststadt-Heidehaus
City
Hannover
ZIP/Postal Code
30459
Country
Germany
Facility Name
Brüderkrankenhaus St. Josef Paderborn
City
Paderborn
ZIP/Postal Code
33098
Country
Germany
Facility Name
Sotiria Chest Hospital of Athens
City
Athens
ZIP/Postal Code
11527
Country
Greece
Facility Name
Attikon University General Hospital
City
Athens
ZIP/Postal Code
12464
Country
Greece
Facility Name
Bioclinic Thessaloniki
City
Thessaloniki
ZIP/Postal Code
546 22
Country
Greece
Facility Name
Georgios Papanikolaou General Hosp. of Thessaloniki
City
Thessaloniki
ZIP/Postal Code
57010
Country
Greece
Facility Name
Semmelweis Egyetem
City
Budapest
ZIP/Postal Code
1083
Country
Hungary
Facility Name
Uzsoki Utcai Korhaz
City
Budapest
ZIP/Postal Code
1145
Country
Hungary
Facility Name
Matrai Gyogyintezet
City
Matrahaza
ZIP/Postal Code
3233
Country
Hungary
Facility Name
Szabolcs-Szatmar-Bereg Megyei; Korhazak es Egyetemi Oktatokorhaz
City
Nyiregyhaza
ZIP/Postal Code
4400
Country
Hungary
Facility Name
University of Pecs, I st Dept of Internal Medicine
City
Pecs
ZIP/Postal Code
7624
Country
Hungary
Facility Name
Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz-Rend.Int.
City
Szolnok
ZIP/Postal Code
5000
Country
Hungary
Facility Name
IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica
City
Meldola
State/Province
Emilia-Romagna
ZIP/Postal Code
47014
Country
Italy
Facility Name
Ospedale Infermi di Rimini
City
Rimini
State/Province
Emilia-Romagna
ZIP/Postal Code
47900
Country
Italy
Facility Name
Irccs Centro Di Riferimento Oncologico (CRO)
City
Aviano
State/Province
Friuli-Venezia Giulia
ZIP/Postal Code
33081
Country
Italy
Facility Name
Asst Papa Giovanni XXIII
City
Bergamo
State/Province
Lombardia
ZIP/Postal Code
24100
Country
Italy
Facility Name
Azienda Ospedaliera Istituti Ospitalieri
City
Cremona
State/Province
Lombardia
ZIP/Postal Code
26100
Country
Italy
Facility Name
Ospedale San Raffaele S.r.l.
City
Milano
State/Province
Lombardia
ZIP/Postal Code
20132
Country
Italy
Facility Name
Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 2
City
Milano
State/Province
Lombardia
ZIP/Postal Code
20133
Country
Italy
Facility Name
Istituto Europeo Di Oncologia
City
Milano
State/Province
Lombardia
ZIP/Postal Code
20141
Country
Italy
Facility Name
Asst Di Monza
City
Monza
State/Province
Lombardia
ZIP/Postal Code
20900
Country
Italy
Facility Name
Istituto Clinico Humanitas
City
Rozzano (MI)
State/Province
Lombardia
ZIP/Postal Code
20089
Country
Italy
Facility Name
Azienda Ospedaliera Città della Salute e della Scienza di Torino
City
Torino
State/Province
Piemonte
ZIP/Postal Code
10126
Country
Italy
Facility Name
A.O.U.I. VERONA-OSPEDALE BORGO TRENTO; ONCOLODIA MEDICA-d.O.
City
Verona
State/Province
Veneto
ZIP/Postal Code
37126
Country
Italy
Facility Name
Seoul National University Bundang Hospital
City
Gyeonggi-do
ZIP/Postal Code
13620
Country
Korea, Republic of
Facility Name
Chonnam National University Hwasun Hospital
City
Jeollanam-do
ZIP/Postal Code
58128
Country
Korea, Republic of
Facility Name
The Catholic University of Korea St. Vincent's Hospital
City
Suwon-si,
ZIP/Postal Code
442-723
Country
Korea, Republic of
Facility Name
Uniwersyteckie Centrum Kliniczne
City
Gdansk
ZIP/Postal Code
80-214
Country
Poland
Facility Name
County Hospital Alba; Oncology
City
Alba Iulia
ZIP/Postal Code
510073
Country
Romania
Facility Name
Dr Constantin Opris Emergency County Hospital Baia Mare
City
Baia Mare
ZIP/Postal Code
430031
Country
Romania
Facility Name
Teo Health SA - Saint Constantin Hospital
City
Brasov
ZIP/Postal Code
500091
Country
Romania
Facility Name
Oncology Center Sf. Nectarie
City
Craiova
ZIP/Postal Code
200347
Country
Romania
Facility Name
Institutul Regional de Oncologie Iasi; Clinica de Hematologie
City
Iasi
ZIP/Postal Code
700483
Country
Romania
Facility Name
Sibiu Emergency Clinical County Hospital
City
Sibiu
ZIP/Postal Code
550245
Country
Romania
Facility Name
Oncomed SRL
City
Timisoara
ZIP/Postal Code
300239
Country
Romania
Facility Name
Arkhangelsk Regional Clinical Oncology Dispensary
City
Arkhangelsk
ZIP/Postal Code
163045
Country
Russian Federation
Facility Name
Kursk Regional Clinical Oncology Dispensary
City
Kursk
ZIP/Postal Code
305035
Country
Russian Federation
Facility Name
Filial #1 Regional Oncology Dispensary of Nizhniy Novgorod
City
Nizhny Novgorod
ZIP/Postal Code
603081
Country
Russian Federation
Facility Name
Mordovia State University
City
Saransk
ZIP/Postal Code
430032
Country
Russian Federation
Facility Name
Leningrad Regional Clinical Hospital
City
St Petersburg
ZIP/Postal Code
194291
Country
Russian Federation
Facility Name
Clinical Hospital Center Bezanijska kosa; Clinic for Oncology
City
Belgrade
ZIP/Postal Code
11000
Country
Serbia
Facility Name
Clin Hospital Center - Kragujevac; Pulmonary Diseases
City
Kragujevac
ZIP/Postal Code
34000
Country
Serbia
Facility Name
Institute of Lung Diseases Vojvodina
City
Sremska Kamenica
ZIP/Postal Code
21204
Country
Serbia
Facility Name
Hospital Universitari Germans Trias i Pujol; Servicio de Oncologia
City
Badalona
State/Province
Barcelona
ZIP/Postal Code
08916
Country
Spain
Facility Name
Fundacion Investigacion Hospital La Fe de Valencia
City
Valencia
ZIP/Postal Code
46026
Country
Spain
Facility Name
Hosp Clinico Univ Lozano Blesa
City
Zaragoza
ZIP/Postal Code
50009
Country
Spain
Facility Name
Birmingham Heartlands Hospital
City
Birmingham
ZIP/Postal Code
B9 5SS
Country
United Kingdom
Facility Name
Diana Princess of Wales Hosp.
City
Grimsby
ZIP/Postal Code
DN33 2BA
Country
United Kingdom
Facility Name
Sarah Cannon Research Institute
City
London
ZIP/Postal Code
W1G 6AD
Country
United Kingdom
Facility Name
Christie Hospital NHS Trust
City
Manchester
ZIP/Postal Code
M20 4BX
Country
United Kingdom
12. IPD Sharing Statement
Learn more about this trial
A Study of Atezolizumab Compared With Gemcitabine Plus (+) Cisplatin or Carboplatin for PD-L1-Selected Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower111)
We'll reach out to this number within 24 hrs